LIBRETTO-001研究中接受或不接受既往免疫检查点抑制剂治疗的NSCLC患者对塞尔帕替尼的超敏反应
基于LIBRETTO-001 1/2期试验截至2019年12月16日入组患者的数据,分析RET融合阳性NSCLC患者中塞尔帕替尼相关超敏反应。329例中22例(7%)发生1-3级超敏反应,研究者归因于塞尔帕替尼,既往ICI治疗者(17例,77%)多于未接受ICI者(5例,23%)。超敏反应可通过支持治疗管理且可逆。
要点
- 塞尔帕替尼相关超敏反应总体发生率低,为7%(22/329)。
- 超敏反应多见于既往接受ICI治疗者(17例,77%),未接受ICI者5例(23%)。
- 19例患者在超敏反应后经剂量调整/支持治疗重启塞尔帕替尼,其中17例仍在治疗。
核心结论
- 塞尔帕替尼相关超敏反应发生率总体较低,且与其他激酶抑制剂类似,主要发生于既往ICI治疗患者。
- 无论既往ICI状态如何,塞尔帕替尼超敏反应可通过支持治疗措施管理,且可逆。
研究设计与样本
- 分析正在进行的1/2期LIBRETTO-001试验(NCT03157128)中截至2019年12月16日入组患者的数据。
主要发现
- 329例患者中22例(7%)发生研究者归因于塞尔帕替尼的1-3级超敏反应,符合预设症状群定义。
- 22例中既往ICI治疗者17例(77%),未接受ICI者5例(23%)。
- 19例患者在超敏反应后经剂量调整/支持治疗重启塞尔帕替尼。
- 17例仍在治疗中,其中14例既往接受ICI治疗,每日两次剂量为40 mg(5例)、80 mg(4例)、120 mg(4例)、160 mg(4例)。
关键数值与推荐
- 超敏反应定义为斑丘疹,常先有发热伴关节痛/肌痛,随后出现以下至少1项:血小板减少、天冬氨酸氨基转移酶或丙氨酸氨基转移酶升高、低血压、心动过速或肌酐升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitor (ICI) therapy has been found to increase the risk/severity of immune-mediated adverse events with subsequent kinase inhibitor treatment in oncogenically driven cancers. We explored the risk for hypersensitivity with selpercatinib, a first-in-class highly selective and potent, central nervous system-active RET inhibitor, in prior ICI-treated patients with RET fusion-positive NSCLC compared with their ICI-naive counterparts. METHODS: Data from patients enrolled by December 16, 2019, in the ongoing phase 1/2 LIBRETTO-001 (NCT03157128) trial were analyzed for hypersensitivity reactions reported using preferred terms of hypersensitivity/drug hypersensitivity and defined as a constellation of symptoms/findings characterized by maculopapular rash, often preceded by fever with arthralgias/myalgias, followed by greater than or equal to 1 of the following signs/symptoms: thrombocytopenia, increased aspartate aminotransferase or alanine aminotransferase, hypotension, tachycardia, or increased creatinine. RESULTS: Of 329 patients, 22 (7%) who experienced a grade 1 to 3 hypersensitivity reaction that met the defined constellation of events were attributed to selpercatinib by investigators, and more often in prior ICI-treated (n = 17, 77%) than ICI-naive (n = 5, 23%) patients. There were 19 patients with selpercatinib-related hypersensitivity who resumed selpercatinib post-hypersensitivity with dose modification/supportive care. Furthermore, 17 patients, of whom 14 received prior ICI therapy, were still on treatment at twice daily doses of 40 mg (n = 5), 80 mg (n = 4), 120 mg (n = 4), and 160 mg (n = 4). CONCLUSIONS: Rates of selpercatinib-related hypersensitivity were low overall and, as with other kinase inhibitors, occurred predominantly in prior ICI-treated patients. Hypersensitivity to selpercatinib can be managed with supportive care measures regardless of prior ICI status and is reversible.
引用
- McCoach CE, Rolfo C, Drilon A, et al. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. J Thorac Oncol. 2022. PMID: 35183775. doi:10.1016/j.jtho.2022.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。